Key result
TF VenoCure2 valvulotome achieves a 96% success rate in non-reversed saphenous vein bypass.
Why the study?
Venous injury by valvulotomes is a risk factor for poor outcomes in PAD with non-reversed saphenous vein bypasses, and safer valvulotome designs are needed.
Observational (n=91)
No
The TF VenoCure2 valvulotome with inward-facing blades demonstrated a 96% technical success rate and a low venous injury rate in non-reversed translocated saphenous vein bypasses.
Should not yet change practice in vein bypass; leaves open need for prospective validation.
Venous injury by a valvulotome is one of the risk factors for poor outcomes in peripheral arterial disease (PAD) with non-reversed saphenous vein bypasses. As I thought that outward-pointing blades might cause intimal damage or tributary laceration, I invented a new valvulotome with tapered 4 blades pointing inward 33 years ago, and have used it for 101 non-reversed translocated saphenous vein bypasses. The TF VenoCure2 (VC; Numata Optical Instruments Factory, Tokyo, Japan) injured 3 veins in the early days, which were easily repaired and used for bypasses. There were 3 cases of early thrombotic occlusion, of which only 1 case was recovered. In another case, the most proximal valve was left uncut, which was resected by venotomy. Thus, the success rate of VC valvulotomy was 96.0% (97/101), including the 3 early occlusion cases. The in-hospital mortality rate was 2.2% (2/91); a patient on hemodialysis died of aspiration pneumonia, and an 89-year-old patient died of deteriorated heart failure. No venous injuries occurred in the consecutive 74 cases during the recent 22 years. From the operative records, the VC cut all the valves with a single procedure with good pulsatile flow in 62 out of 67 cases (92.5%). The VC is a new device for safe and reliable valvulotomy in PAD surgery. (This is a secondary publication from J Jpn Coll Angiol 2025; 65: 55-61.)
No takes yet. Share an insight, caveat, or question.
古屋 et al. (2026) conducted an observational in Peripheral arterial disease (n=91). Tapered 4-Bladed Valvulotome (TF VenoCure2) was evaluated on Success rate of valvulotomy (adequate pulsatile flow). The TF VenoCure2 valvulotome achieved a 96.0% success rate in non-reversed translocated saphenous vein bypass surgeries, with no venous injuries in the most recent 74 consecutive cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: